Abstract
Glioblastomas, which are the most common primary intracranial tumor, are associated with the poorest survival time, which is typically 1-2 years. Age at initial diagnosis, Karnofsky performance score, and O(6)-methylguanine DNA-methyltransferase (MGMT) promoter methylation status are the most well-documented predictors of survival in patients with newly diagnosed glioblastoma. Few studies have examined prognostic factors in patients with recurrent glioblastomas. At relapse, the pathological features of glioblastomas are affected by tumor regrowth and the influence of chemoradiotherapy during the initial treatment. Morphological transformations at recurrence include quantitative changes in tumor cells, such as the presence of giant cells and gemistocytic cell formation, radiation necrosis, and vascular structural changes. Therefore, we should carefully examine pathological findings at recurrence. In this report, we analyzed MGMT promoter status, the MIB-1 index, and the pathology of tumor samples at the first (primary tumor) and second (recurrent tumor) surgeries and clarified prognostic factors in patients with recurrent cases. In the multivariate analysis, we showed that MIB-1 indexes at the time of the second surgery (p = 0.0...Continue Reading
References
Dec 1, 1985·Neurologia Medico-chirurgica·M OgashiwaK Akai
Apr 1, 1987·Neurologia Medico-chirurgica·M OgashiwaK Akai
Aug 1, 1987·Neurosurgery·M AmmiratiM Mikhael
May 1, 1974·Neurology·N Willson, P E Duffy
Jan 1, 1997·Journal of Neurosurgery·J M CunninghamR B Jenkins
Sep 11, 1999·Neurologia Medico-chirurgica·K KunishioT Ohmoto
Jan 10, 2001·Neurological Research·T KoderaS Hirose
Jan 10, 2002·Journal of Neurosurgery·M LacroixR Sawaya
Mar 8, 2002·Pathology Oncology Research : POR·A M RalteC Sarkar
May 9, 2002·Journal of Neuro-oncology·Roland SchröderRalf-Ingo Ernestus
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Oct 20, 2005·Journal of Neuro-oncology·Shaye I MoskowitzRichard A Prayson
Dec 13, 2006·Neurosurgical Focus·C B SoultsT C Ryken
Feb 3, 2007·Acta neurochirurgica·J-F MineoP Dam-Hieu
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn A CarsonEdward G Shaw
Nov 16, 2007·Journal of Neuro-oncology·Jonathon F ParkinsonKerrie L McDonald
Dec 18, 2007·The Lancet Oncology·Thierry GorliaRoger Stupp
Dec 25, 2007·Japanese Journal of Clinical Oncology·Motoo NaganeYoshiaki Shiokawa
Apr 11, 2008·Brain Pathology·Matthias PreusserMonika Hegi
Mar 10, 2009·The Lancet Oncology·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 20, 2010·Neuro-oncology·Alba A BrandesMario Ermani
Apr 8, 2010·Oncology Reports·Tae-Young JungKyung-Hwa Lee
Apr 30, 2010·Oncology Reports·Bruno M CostaRui M Reis
Feb 9, 2011·Neurosurgical Review·Tomoo InoueTeiji Tominaga
Citations
Dec 12, 2012·Cancer Chemotherapy and Pharmacology·Soichiro ShibuiKazuhiro Nomura
Jan 26, 2013·Anti-cancer Drugs·Osnat Ashur-FabianAleck Hercbergs
Dec 19, 2012·Journal of Translational Medicine·Consolación MelguizoAntonia Aránega
Jan 1, 2014·CNS Oncology·James S HaleJustin D Lathia
Jan 28, 2014·Neuro-oncology·Francesca NavaGraziella Filippini
Sep 19, 2015·Clinical Oncology : a Journal of the Royal College of Radiologists·C GzellM Back
Aug 29, 2012·Neurological Research·Sung-Geun ParkSam-Suk Kang
Nov 1, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·A Dullea, L Marignol
Feb 23, 2018·Experimental and Therapeutic Medicine·Liang LiuShuai Wen
Aug 3, 2017·Neuropathology and Applied Neurobiology·M D SørensenB W Kristensen
Feb 17, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Wen-Jie ChenGang Chen
Oct 19, 2013·Oncology Letters·Pin GuoYongming Qiu
Jan 13, 2021·Cancers·Jen-Fu HsuMing-Horng Tsai
Jun 28, 2012·Radiation Oncology·Kazuyuki UeharaRyohei Sasaki
Sep 11, 2021·Scientific Reports·Rikke H DahlrotBjarne W Kristensen